sEV from 3D‐Cultured MSCs Engineered with miR‐27b‐3p for Treating TMJ‐OA by Suppressing Osteoclastogenesis
Small · 2025-11 · 21 (46)
DOI: 10.1002/smll.202504482 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 29.09.2025. Verfasst von Jie Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Weijin Road 94th, Tianjin, 300071, P. R. C…. Hauptthemen laut MEDLINE: MicroRNAs, Mesenchymal Stem Cells, Osteoarthritis, Osteogenesis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Tianjin Health Research Project, Scientific Research program of Tianjin Education Commission, Jinan Clinical Medical Science and Technology Innovation Plan.
Abstract (Originalsprache)
Temporomandibular joint osteoarthritis (TMJ‐OA), a refractory osteoarticular disorder, is critically hindered by inflammation‐mediated bone metabolic imbalance during disease progression. Building on the previous discovery that inflammation‐indued mesenchymal stem cell‐derived small extracellular vesicles (sEV) regulate macrophage polarization via the miR‐27b‐3p/CSF‐1 axis, functionally enhanced engineered sEV (sEV‐r) is developed through 3D dynamic culture coupled with electroporation technology. This strategy leverages 3D culture to optimize vesicle bioactivity and employs electroporation for high‐efficiency miR‐27b‐3p loading, endowing sEV‐r with both inherent targeting capacity and amplified anti‐inflammatory functionality. Experimental validation demonstrate that sEV‐r effectively suppresses CSF‐1‐driven inflammatory cascades via efficient miR‐27b‐3p delivery while enhancing the chemotactic migration of bone marrow mesenchymal stem cells (BMSCs). In vivo studies demonstrate that sEV‐r exhibits superior therapeutic efficacy in both acute inflammatory (mouse ear edema) and chronic osteoarthritic (TMJ‐OA) models. In TMJ‐OA models, sEV‐r exert dual therapeutic mechanisms: modulating macrophage phenotype polarization to optimize the inflammatory microenvironment, and inhibiting oxidative stress to block abnormal osteoclast activation. These effects collectively improve subchondral bone microstructure and restore bone metabolic equilibrium. This study establishes a novel engineering strategy for sEV‐based targeted therapy, providing critical insights into precision interventions for TMJ‐OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Weijin Road 94th, Tianjin, 300071, P. R. China.
- Department of Occlusion and Temporomandibular Joint Diseases, Tianjin Stomatological Hospital, School of Medicine, Nankai University, Tianjin, 300041, P. R. China.
- Tianjin Key Laboratory of Oral and Maxillofacial Function Reconstruction, Tianjin, 300041, P. R. China.
- Nankai International Advanced Research Institute (SHENZHEN FUTIAN), Shenzhen, Guangdong, 518045, P. R. China.
ORCID-Profile: Shufang Wang
Förderung
- Tianjin Health Research Project
- Scientific Research program of Tianjin Education Commission
- Jinan Clinical Medical Science and Technology Innovation Plan
- Tianjin Research Program of Application Foundation and Advanced Technology of China
Zitieren
APA
Zhou, J., Zhang, Z., Fu, S., Xu, L., Wang, Y., Hu, Z., Midgley, A. C., Liu, Y., & Wang, S. (2025). sEV from 3D‐Cultured MSCs Engineered with miR‐27b‐3p for Treating TMJ‐OA by Suppressing Osteoclastogenesis. Small, 21(46). https://doi.org/10.1002/smll.202504482
Vancouver
Zhou J, Zhang Z, Fu S, Xu L, Wang Y, Hu Z, et al. sEV from 3D‐Cultured MSCs Engineered with miR‐27b‐3p for Treating TMJ‐OA by Suppressing Osteoclastogenesis. Small. 2025;21(46). doi:10.1002/smll.202504482
BibTeX
@article{Zhou2025,
author = {Zhou, Jie and Zhang, Zhiling and Fu, Shuang and Xu, Lulu and Wang, Yukang and Hu, Zhihui and Midgley, Adam C and Liu, Yufei and Wang, Shufang},
title = {sEV from 3D‐Cultured MSCs Engineered with miR‐27b‐3p for Treating TMJ‐OA by Suppressing Osteoclastogenesis},
journal = {Small},
year = {2025},
volume = {21},
number = {46},
doi = {10.1002/smll.202504482}
}
EUVIMED